L-364,373（Cat No.:M005268）is a selective, orally bioavailable inhibitor of the HIV-1 protease enzyme, a critical enzyme in the replication cycle of the human immunodeficiency virus (HIV). By inhibiting the HIV-1 protease, L-364,373 prevents the maturation of viral particles, reducing the ability of the virus to infect new cells. This compound has shown potential in preclinical studies as part of a broader strategy to manage HIV infection. While its clinical development may be limited, it contributes to research in HIV treatment, particularly in combination therapies aimed at overcoming resistance to current protease inhibitors.